Harbin Pharmaceutical Group Co Ltd (SHG:600664) — Market Cap & Net Worth
Market Cap & Net Worth: Harbin Pharmaceutical Group Co Ltd (600664)
Harbin Pharmaceutical Group Co Ltd (SHG:600664) has a market capitalization of $1.39 Billion (CN¥9.47 Billion) as of May 10, 2026. Listed on the SHG stock exchange, this China-based company holds position #7785 globally and #1957 in its home market, demonstrating a 2.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Harbin Pharmaceutical Group Co Ltd's stock price CN¥3.76 by its total outstanding shares 2518509876 (2.52 Billion). Analyse Harbin Pharmaceutical Group Co Ltd (600664) cash conversion ratio to see how efficiently the company converts income to cash.
Harbin Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Harbin Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.88 Billion to $1.39 Billion (-5.37% CAGR).
Index Memberships
Harbin Pharmaceutical Group Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$4.17 Trillion | 0.03% | #251 of 285 |
Weight: Harbin Pharmaceutical Group Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Harbin Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Harbin Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Harbin Pharmaceutical Group Co Ltd's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.42x
Harbin Pharmaceutical Group Co Ltd's market cap is 2.42 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.88 Billion | $15.86 Billion | $580.13 Million | 0.18x | 4.97x |
| 2016 | $2.69 Billion | $14.13 Billion | $788.10 Million | 0.19x | 3.42x |
| 2017 | $1.95 Billion | $12.02 Billion | $406.98 Million | 0.16x | 4.78x |
| 2018 | $1.46 Billion | $10.81 Billion | $346.14 Million | 0.13x | 4.21x |
| 2019 | $1.40 Billion | $11.82 Billion | $55.81 Million | 0.12x | 25.03x |
| 2020 | $1.18 Billion | $10.79 Billion | -$1.08 Billion | 0.11x | N/A |
| 2021 | $1.31 Billion | $12.80 Billion | $371.08 Million | 0.10x | 3.53x |
| 2022 | $1.11 Billion | $13.81 Billion | $465.15 Million | 0.08x | 2.38x |
| 2023 | $1.23 Billion | $15.46 Billion | $395.26 Million | 0.08x | 3.12x |
| 2024 | $1.52 Billion | $16.18 Billion | $628.85 Million | 0.09x | 2.42x |
Competitor Companies of 600664 by Market Capitalization
Companies near Harbin Pharmaceutical Group Co Ltd in the global market cap rankings as of May 10, 2026.
Key companies related to Harbin Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #498 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #538 globally with a market cap of $49.29 Billion USD ( CN¥336.81 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #571 globally with a market cap of $45.88 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #654 globally with a market cap of $40.57 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #498 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.29 Billion | CN¥52.80 |
| #571 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.27 |
| #654 | Haleon plc | NYSE:HLN | $40.57 Billion | $9.11 |
Harbin Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Harbin Pharmaceutical Group Co Ltd's market cap moved from $2.88 Billion to $ 1.39 Billion, with a yearly change of -5.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.39 Billion | +8.99% |
| 2025 | CN¥1.27 Billion | -16.46% |
| 2024 | CN¥1.52 Billion | +23.28% |
| 2023 | CN¥1.23 Billion | +11.30% |
| 2022 | CN¥1.11 Billion | -15.21% |
| 2021 | CN¥1.31 Billion | +11.29% |
| 2020 | CN¥1.18 Billion | -15.83% |
| 2019 | CN¥1.40 Billion | -4.05% |
| 2018 | CN¥1.46 Billion | -25.23% |
| 2017 | CN¥1.95 Billion | -27.75% |
| 2016 | CN¥2.69 Billion | -6.50% |
| 2015 | CN¥2.88 Billion | -- |
End of Day Market Cap According to Different Sources
On May 10th, 2026 the market cap of Harbin Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.39 Billion USD |
| MoneyControl | $1.39 Billion USD |
| MarketWatch | $1.39 Billion USD |
| marketcap.company | $1.39 Billion USD |
| Reuters | $1.39 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Harbin Pharmaceutical Group Co Ltd
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cere… Read more